TY - JOUR
T1 - Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure
T2 - a target trial emulation
AU - Watanabe, Atsuyuki
AU - Miyamoto, Yoshihisa
AU - Ueyama, Hiroki A.
AU - Inoue, Kosuke
AU - Laham, Roger
AU - Bhatt, Deepak L.
AU - Tsugawa, Yusuke
AU - Kuno, Toshiki
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
PY - 2025
Y1 - 2025
N2 - Background Percutaneous ventricular assist devices (pVAD) have been increasingly used to support haemodynamics during percutaneous coronary interventions (PCI). Since older patients with coronary artery disease and heart failure (HF) are less likely to undergo open heart surgery, given the higher risk of perioperative complications, the analyses on the benefits of pVAD for older patients with HF receiving PCI will be informative. Methods We included Medicare fee-for-service beneficiaries aged 65–99 years with systolic HF receiving PCI from 2017 to 2020. Using a target trial emulation framework, we followed the patients from the date of the index PCI to the maximum of 1 year and examined the incidence of major adverse cardiovascular events (MACE: composite of all-cause mortality, HF readmission, acute myocardial infarction, and stroke), as well as in-hospital outcomes, including postprocedural transfusions, of patients treated with PCI plus pVAD versus PCI plus intra-aortic balloon pump (IABP). We used the propensity score matching approach to control for 58 baseline covariates and applied a Cox regression model to estimate adjusted hazard ratio (aHR). Results We included 5823 patients, from whom 2096 patients were matched. The risk of 1-year MACE was 55.4% (95% CI 52.2–58.5) in the pVAD group versus 54.7% (95% CI 51.4 to 57.8) in the IABP group, with aHR of 0.95 (95% CI 0.83 to 1.10). We did not find evidence that other outcomes differed between patients treated with PCI plus pVAD versus PCI plus IABP, including 1-year mortality (aHR, 0.94; 95% CI,0.79 to 1.12) and postprocedural transfusions (adjusted risk ratio, 1.07; 95% CI 0.75 to 1.52). Our findings were consistent across several sensitivity analyses. Conclusions This observational study using the Medicare databases in the USA did not find evidence that clinical outcomes differed between older patients with systolic HF receiving PCI with pVAD vs PCI plus IABP.
AB - Background Percutaneous ventricular assist devices (pVAD) have been increasingly used to support haemodynamics during percutaneous coronary interventions (PCI). Since older patients with coronary artery disease and heart failure (HF) are less likely to undergo open heart surgery, given the higher risk of perioperative complications, the analyses on the benefits of pVAD for older patients with HF receiving PCI will be informative. Methods We included Medicare fee-for-service beneficiaries aged 65–99 years with systolic HF receiving PCI from 2017 to 2020. Using a target trial emulation framework, we followed the patients from the date of the index PCI to the maximum of 1 year and examined the incidence of major adverse cardiovascular events (MACE: composite of all-cause mortality, HF readmission, acute myocardial infarction, and stroke), as well as in-hospital outcomes, including postprocedural transfusions, of patients treated with PCI plus pVAD versus PCI plus intra-aortic balloon pump (IABP). We used the propensity score matching approach to control for 58 baseline covariates and applied a Cox regression model to estimate adjusted hazard ratio (aHR). Results We included 5823 patients, from whom 2096 patients were matched. The risk of 1-year MACE was 55.4% (95% CI 52.2–58.5) in the pVAD group versus 54.7% (95% CI 51.4 to 57.8) in the IABP group, with aHR of 0.95 (95% CI 0.83 to 1.10). We did not find evidence that other outcomes differed between patients treated with PCI plus pVAD versus PCI plus IABP, including 1-year mortality (aHR, 0.94; 95% CI,0.79 to 1.12) and postprocedural transfusions (adjusted risk ratio, 1.07; 95% CI 0.75 to 1.52). Our findings were consistent across several sensitivity analyses. Conclusions This observational study using the Medicare databases in the USA did not find evidence that clinical outcomes differed between older patients with systolic HF receiving PCI with pVAD vs PCI plus IABP.
KW - Coronary Artery Disease
KW - Heart Failure
KW - Heart-Assist Devices
UR - https://www.scopus.com/pages/publications/105021659933
U2 - 10.1136/heartjnl-2025-326949
DO - 10.1136/heartjnl-2025-326949
M3 - Article
C2 - 41218925
AN - SCOPUS:105021659933
SN - 1355-6037
JO - Heart
JF - Heart
M1 - heartjnl-2025-326949
ER -